For example, Halpern et al. found an approximately 3-fold increased rate of high RS among BRCA1/2 carriers with ER+ breast cancer in comparison with a large group of patients from the general population and concluded that this “might indicate that hormone-positive breast cancers in BRCA carriers are molecularly unique”20. This evidence concerns the gene BRCA1 and breast carcinoma.